

RESEARCH

Open Access

# Immunomodulatory properties of stem cells from human exfoliated deciduous teeth

Takayoshi Yamaza<sup>1,2,#</sup>, Akiyama Kentaro<sup>1,#</sup>, Chider Chen<sup>1</sup>, Yi Liu<sup>1</sup>, Yufang Shi<sup>3</sup>, Stan Gronthos<sup>4</sup>, Songlin Wang<sup>5</sup>, Songtao Shi<sup>\*1</sup>

## Abstract

**Introduction:** Stem cells from human exfoliated deciduous teeth (SHED) have been identified as a population of postnatal stem cells capable of differentiating into osteogenic and odontogenic cells, adipogenic cells, and neural cells. Herein we have characterized mesenchymal stem cell properties of SHED in comparison to human bone marrow mesenchymal stem cells (BMMSCs).

**Methods:** We used *in vitro* stem cell analysis approaches, including flow cytometry, inductive differentiation, telomerase activity, and Western blot analysis to assess multipotent differentiation of SHED and *in vivo* implantation to assess tissue regeneration of SHED. In addition, we utilized systemic SHED transplantation to treat systemic lupus erythematosus (SLE)-like MRL/lpr mice.

**Results:** We found that SHED are capable of differentiating into osteogenic and adipogenic cells, expressing mesenchymal surface molecules (STRO-1, CD146, SSEA4, CD73, CD105, and CD166), and activating multiple signaling pathways, including TGF $\beta$ , ERK, Akt, Wnt, and PDGF. Recently, BMMSCs were shown to possess an immunomodulatory function that leads to successful therapies for immune diseases. We examined the immunomodulatory properties of SHED in comparison to BMMSCs and found that SHED had significant effects on inhibiting T helper 17 (Th17) cells *in vitro*. Moreover, we found that SHED transplantation is capable of effectively reversing SLE-associated disorders in MRL/lpr mice. At the cellular level, SHED transplantation elevated the ratio of regulatory T cells (Tregs) via Th17 cells.

**Conclusions:** These data suggest that SHED are an accessible and feasible mesenchymal stem cell source for treating immune disorders like SLE.

## Introduction

Human bone marrow mesenchymal stem cells (BMMSCs) have been identified as a population of postnatal stem cells with the potential to self-renew and differentiate into osteoblasts, chondrocytes, adipocytes, and neural cells [1-5]. BMMSCs also exhibit immunomodulatory and regulatory effects on T and B lymphocytes, dendritic cells, and natural killer cells, indicating an attractive feature for cell therapy [6-11]. In addition, culture expanded BMMSCs may fail to express MHC-class II antigens on their surfaces, therefore allogenic BMMSCs have been used in treating a variety of diseases such as acute graft-versus-host-disease (GVHD) [12-14],

ameliorating Hematopoietic Stem Cell engraftment [15, 16], and systemic lupus erythematosus (SLE) [17]. Recently, mesenchymal stem cells derived from other tissues have also been found to possess immunomodulatory functions [18-20] which offer opportunities to find more effective and feasible mesenchymal stem cell sources for cell therapies.

Stem cells from human exfoliated deciduous teeth (SHED) have been isolated from naturally exfoliated deciduous teeth with the capacity to differentiate into osteogenic and odontogenic cells, adipocytes, and neural cells [21]. As neural crest cell-associated postnatal stem cells, SHED express a variety of neural cell markers including nestin, beta III tubulin, GAD, NeuN, GFAP, NFM, and CNPase [21]. Also, SHED are able to form bone when transplanted *in vivo* [22] and offer obvious bone regeneration for repairing calvarial defects in a mouse model [23]. It is unknown whether SHED possess

<sup>#</sup>Contributed equally.

\*Correspondence: songtaos@usc.edu

<sup>1</sup>Center for Craniofacial Molecular Biology, University of Southern California School of Dentistry, 2250 Alcazar Street, CSA 103, Los Angeles, CA 90033, USA  
Full list of author information is available at the end of the article

immunomodulatory function as seen in BMMSCs. In this study, we compare immuno-regulatory properties between SHED and BMMSCs and utilize SHED transplantation to treat SLE-like diseases in a murine model.

## Materials and methods

### Mice

C57BL/6J and C3MRL-Fas<sup>lpr</sup>/J (MRL/lpr) mice (female, six- to seven-week-old) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Beige *nude/nude* Xid (III) mice (female, 8- to 12-week-old) were purchased from Harlan (Indianapolis, IN, USA). All animal experiments were performed under an institutionally approved protocol for the use of animal research (University of Southern California protocol #10874 and #10941).

### Human tooth, bone marrow and peripheral blood samples

Human exfoliated deciduous incisors were obtained as discarded biological samples from children (six- to eight-year-old) at the Dental Clinic of the University of Southern California following the approved Institutional Review Board guidelines. Healthy bone marrow aspirates from iliac bone and peripheral blood mononuclear cells (PBMNCs) of healthy volunteers were purchased from AllCells (Berkeley, CA, USA).

### Isolation and culture of SHED and BMMSCs

Mononuclear cells isolated from the remnant dental pulp tissue of the deciduous incisors were cultured as reported previously [21, 24]. BMMSCs culture was described previously [25]. The detailed protocols were described in Additional file 1.

### Cell surface markers analysis

The procedure for single colored flow cytometry (FCM) was performed as described previously [26, and Additional file 1]. The samples were analyzed on a FACSCalibur flow cytometer (BD Bioscience, San Jose, CA, USA). Some cells were used for immunoblot analysis and immunofluorescent staining.

### Colony forming units-fibroblastic (CFU-F) assay

CFU-F assay was performed according to a previous study [27, and Additional file 1].

### Cell proliferation assay

The proliferation of each MSC population was performed by bromodeoxyuridine (BrdU) incorporation assay as previously described [21, 27 and Additional file 1].

### Telomerase activity assay

Telomerase activity was evaluated by telomeric repeat amplification protocol (TRAP) assay using real-time polymerase chain reaction (PCR) [28, and Additional file 1].

### *In vitro* osteogenic induction assay

Osteogenic differentiation assays of SHED and BMMSCs were performed according to previous publications [21, 28]. Osteogenic markers and mineralized nodule formation were assessed as described previously [21, 28 and Additional file 1].

### Adipogenic induction assay *in vitro*

Adipogenic assay *in vitro* of each stem cell population was performed as described previously [21, 28, and Additional file 1].

### *In vivo* osteogenic differentiation

Xenogeneic transplantation was performed using immunocompromised mice as described [21, 25, 26]. Each MSC population was subcutaneously transplanted into beige *nude/nude* Xid (III) mice using hydroxyapatite tricalcium phosphate (HA/TCP) as a carrier. Eight weeks post-transplantation, the transplants were harvested for histological analysis. Detail methods were described in the Additional file 1.

### Immunoblot analysis

Ten µg total protein was loaded and analyzed by immunoblotting as previously described [21, 28, and Additional file 1].

### Co-culture of human PBMNCs or T lymphocytes with SHED or BMMSCs

PBMNCs or T cells were co-cultured with or without SHED or BMMSCs under several culture conditions as described in Additional file 1. Cell death analysis and induction of Tregs and Th17 cells were described in Additional file 1.

### Xenogeneic SHED or human BMMSCs into MRL/lpr mice

Under general anesthesia, SHED or BMMSCs ( $1 \times 10^5$  cells/10g body weight in 100 µl PBS) were infused into MRL/lpr mice via tail vein at 16 weeks (n = 3) according to previous study [17]. MRL/lpr mice (16-week-old) received physiological saline (n = 3) were used as experimental control mice. All mice were sacrificed at 20 weeks of age, and from them were collected peripheral blood, kidney, and long bones (femur and tibiae).

### FCM analysis of Treg and Th17 cells

Flow cytometric staining and analysis were performed as previously reported [29, and Additional file 1].

### Measurement of biomarkers in culture supernatant, blood serum and urine

Several biomarkers, including anti-dsDNA antibody and anti-nuclear antibody ANA, complement 3 (C3), interleukin 6 (IL6), IL10, IL17, soluble receptor activator for

nuclear factor  $\kappa$ B ligand (sRANKL), and C-terminal telopeptides of type I collagen (CTX), creatinine, urine protein in biofluid samples (peripheral blood serum and urine) were measured by enzyme linked immunosorbent assay (ELISA) [17, and Additional file 1].

#### **Histological analysis of kidney and bone**

Kidneys and long bones (femurs) harvested from mice were fixed and processed to make paraffin sections. The sections were used for further experiments [Additional file 1].

#### **Histometry**

Histomorphometric analysis was quantified as described previously [25]. Detailed methods were described in Additional file 1.

#### **Statistics**

All data are expressed as the mean  $\pm$  SD of, at least, triplicate determinations. Statistical difference between the values was examined by Student's t-test. The *P* values less than 0.05 were considered significant.

#### **Antibodies and primer**

All primary antibodies used in this study were described in Additional file 1 and listed on Table S1 in Additional file 1. All primer pairs were listed in Table S2 in Additional file 1

### **Results**

#### **SHED possess mesenchymal stem cell properties**


Although SHED are capable of differentiating into a variety of cell types [21], their detailed mesenchymal stem cell properties remain to be elucidated. Herein, we used flow cytometry, immunoblot analysis, and immunocytochemical analysis to demonstrate that SHED at passage 3 expressed many mesenchymal surface markers, including STRO-1, SSEA4, CD73, CD105, CD146, and CD166 but were negative for CD34 and CD45 (Figures 1A-1C). In comparison to BMMSCs, SHED expressed significantly higher levels of STRO-1 and CD146, and lower levels of CD105 (Figure 1A). Additionally, SHED showed significantly high numbers of single colony clusters (colony-forming units-fibroblastic; CFU-F) and an elevated cell proliferation rate compared to BMMSCs (Figures 1D and 1E). This elevated proliferative capacity may be associated with the significantly increased telomerase activity in SHED (Figure 1F).

To compare osteogenic differentiation of SHED with BMMSCs, multiple colony-derived SHED at passage 3 were supplemented with L-ascorbate-2-phosphate, dexamethasone, and inorganic phosphate to induce mineralization *in vitro* as described previously [21]. After one week of induction, SHED were similar to BMMSCs,

showing significantly increased alkaline phosphatase (ALP) activity (Figure 2A) and the number of ALP-positive cells by flow cytometric analysis (Figure 2B), and expression of elevated levels of ALP, Runt related transcription factor 2 (Runx2), dentin sialoprotein (DSP), and osteocalcin (OCN) by immunoblot analysis (Figure 2C). Alizarin Red-positive nodule formation in SHED and BMMSC cultures was notified after four weeks of osteogenic induction, indicating calcium accumulation *in vitro* (Figures 2D and 2E). However, SHED suffered remarkable impairment of adipogenic differentiation, as shown by decreased numbers of lipid-specific Oil red O-positive cells and reduced expression of adipocyte-specific molecules, peroxisome proliferator-activated receptor  $\gamma$ 2 (PPAR $\gamma$ 2) and lipoprotein lipase (LPL) when compared to BMMSCs (Figures 2F-2H). To validate the capacity of forming mineralized tissue *in vivo* by SHED, *ex vivo* expanded-SHED were transplanted into immunocompromised mice with hydroxyapatite/tricalcium phosphate (HA/TCP) as a carrier. SHED formed a similar amount of mineralized tissue and a reduced amount of hematopoietic marrow components when compared to BMMSC transplants (Figures 2I-2K). Next, we confirmed that SHED were similar to BMMSCs in activation of multiple signaling pathways, including TGF $\beta$ , ERK, Akt, Wnt, and PDGF (Figures 2L-2P).

#### **Interplays between SHED and T-lymphocytes**

In order to compare the immunomodulatory capacity of SHED with BMMSCs, anti-CD3/CD28 antibodies with TGF $\beta$ /IL-6 were added to the co-cultures of SHED or BMMSCs with naive T cells, which were purified from human PBMCs, levels of IL17<sup>+</sup>IFN $\gamma$  Th17 cells and IL17 were significantly reduced in SHED and BMMSC groups compared to the naive T cell group (Figure 3A). It appeared that SHED showed a significant inhibiting effect in reducing IL17 levels when compared to BMMSCs (Figure 3B). Our previous report indicated that activated T cells induce apoptosis of BMMSCs through the Fas/FasL pathway [28]. To determine whether activated T cells also directly impinge on SHED, as occurs in BMMSCs, SHED were co-cultured with human PBMCs activated by anti-CD3 specific antibody treatment. We found that the activated PBMCs were able to induce part of SHED death in the co-culture system (Figure 3C). When SHED were separated from PBMCs using a Transwell co-culture system or treated using anti-FasL neutralizing antibody, SHED failed to show the cell death (Figure 3C), suggesting that direct cell-cell contact and the Fas/FasL pathway are required for inducing SHED death by activated splenocytes. Next, we confirmed that SHED express Fas by immunoblot analysis (Figure 3D). Terminal deoxynucleotidyl transferase-mediated



**Figure 1. Characterization of SHED in comparison to BMMSCs.** (A) Flow cytometric analysis of cultured SHED at passage 3 revealed expression of STRO-1 (12.06%), CD146 (48.39%), SSEA4 (85.40%), CD73 (91.93%), CD105 (6.77%), CD166 (63.65%), but was negative for surface molecules CD34 and CD45. SHED express high levels of STRO-1 and CD146 ( $n = 5$ ;  $P < 0.05$ ) and low level of CD105 ( $n = 5$ ;  $P < 0.01$ ) compared to expression levels of STRO-1 (8.36%), CD146 (31.19%), and CD105 (13.27%) in BMMSCs. These signals are shown as the red area. Solid lines indicate signals for isotype matched control antibodies. M1 window show the positive expression defined as the level of fluorescence greater than 99% of the corresponding isotype-matched control antibodies. Representative histograms are shown among five donors. (B) Immunoblot analysis confirmed expression of CD73, CD105 and CD166 in SHED and BMMSCs. Representative images of  $n = 5$  donors are presented as results. (C) Immunofluorescence confirmed that SHED express STRO-1, CD146, and SSEA4 along with negative for CD34 and CD45. Red fluorescence indicates the expression of cell surface markers. Blue cell nuclei were stained by DAPI. Images were representative data of independent experiment ( $n = 5$ ) with consistent results (Bar = 50 $\mu$ m). (D) SHED were able to form significantly high numbers of single colonies than BMMSCs when  $1 \times 10^6$  cells were plated at a low density ( $*P < 0.05$ ) and cultured for 10 days. (E) The proliferation rates of SHED and BMMSCs were assessed by co-culture with BrdU for 18 hours. The number of BrdU-positive cells was presented as a percentage of the total number of cells counted from five replicate cultures. SHED showed a significantly higher proliferation rate in comparison to BMMSCs ( $**P < 0.01$ ). (F) SHED showed a high activity of telomerase compared to BMMSCs assessed by real time PCR. HEK293T cells (293T) were used as a positive control and heat inactivated 293T (H.I.) cells were used as a negative control. The activity was indicated by a PCR cycle threshold and averaged from three replicated cultures ( $***P < 0.001$ ).


dUTP-biotin nick end labeling (TUNEL) staining was used to confirm that the SHED death was due to cell apoptosis (Figure 3E).

#### SHED transplantation improves SLE phenotypes in MRL/lpr mice

Our previous study showed that systemic infusion of BMMSCs offers appropriate treatment for SLE disorders in human patients and SLE-like MRL/lpr mice [17]. Here we selected SLE-like mice at 16 weeks of age to infuse SHED for treating SLE disorders using BMMSCs as a


control (Figure 4A). It is known that autoantibodies play a crucial role in SLE patients. Our previous study showed a remarkable increase in the levels of autoantibodies including anti-double strand DNA (dsDNA) IgG and IgM antibodies, and anti-nuclear antibody (ANA) in the peripheral blood [17]. As seen in BMMSC transplantation, SHED transplantation resulted in a significant reduction in serum levels of anti-dsDNA IgG and IgM, and ANA antibodies (Figures 4B-4D).

Histological analysis with hematoxylin and eosin, trichrome, and periodic acid-Schiff staining revealed that



SHED transplantation was similar to BMMSC transplantation in recovery of SLE-associated renal disorders, such as nephritis with glomerular basal membrane disorder and mesangial proliferation in MRL/lpr mice (Figure 4E). ELISA data showed that SHED and BMMSC transplantation was able to reduce the urine C3 level and elevate the serum C3 level (Figure 4F). Also,

SHED transplantation significantly reduced urine protein levels compared to BMMSC transplantation (Figure 4G). Moreover, SHED and BMMSC transplantation significantly elevated creatinine levels in urine and reduced creatinine levels in serum (Figure 4H). This experimental evidence indicated that SHED transplantation is an effective approach for treating SLE disorders.



### SHED transplantation regulates ratio of Tregs and Th17 cells


Tregs prevent pathogenic autoimmunity by suppressing proliferation and production of pro-inflammatory cytokines in effector immune cells, such as helper T-lymphocytes [30]. In contrast, Th17 cells that produce IL17 are inflammatory cells responsible for the pathogenesis of autoimmune diseases [31] and bone destruction [32]. Our previous study suggested that BMMSC transplantation affects the immune balance between Tregs and Th17 cells in SLE-like disorders [17]. Here we found that SHED transplantation showed more significant effect in up-regulating the ratio of Treg and Th17 cells in comparison to BMMSC transplantation in MRL/lpr mice (Figures 5A-5C). Both SHED and BMMSC transplantations showed no significant changes in the level of IL10 and IL6 in MRL/lpr mice (Figures 5D and 5E); however, SHED transplantation provided a remarkable reduction of TH17 cells and IL17 level in MRL/lpr mice when compared to BMMSC transplantation (Figures 5C and 5F).

Our previous study suggested that BMMSC transplantation-mediated therapy in SLE-like mice may

associate with the reconstructing trabecular bone [17]. Here we found SHED were also capable of reconstructing trabecular bone in MRL/lpr mice (Figure 6A). In contrast to BMMSC/osteoblast lineage, osteoclasts play a significant role in the maintenance of bone homeostasis by the bone resorption function. We compared SHED transplantation with BMMSC transplantation in inhibiting osteoclast activity in MRL/lpr mice and found that both SHED and BMMSC transplantation were able to reduce the number of tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts in the distal femur epiphysis of MRL/lpr mice (Figure 6B), serum levels of runt-related NF-κB ligand (RANKL), a critical factor for osteoclastogenesis (Figure 6C), and bone resorption marker C-terminal telopeptides of type I collagen (CTX;) as compared to untreated MRL/lpr mice (Figure 6D).

### Discussion



BMMSCs have been successfully utilized to treat a variety of human diseases, such as bone fracture [33], severe aplastic anemia [34], acute GVHD [13], and SLE [17]. SLE is a common and potentially fatal immune disease in



which autoantibodies damage multiple organs, including the kidneys, cardiovascular system, nervous system, joints, and skin [35]. The pathology of SLE involves the destruction of targeted organ tissues and accumulation of auto-reactive lymphocytes and immune complexes. Although intensity and organ involvement vary significantly among SLE patients, abnormalities of T and B lymphocytes are universal [35-37]. Moreover, SLE provokes multifaceted immune modulation, including both deficiency and hyperactivity of the immune system. An understanding of the underlying pathology is crucial to developing optimal therapies for the restoration of immune homeostasis without compromising the protective immune responses to pathogens [38]. MRL/lpr mice were generated by the insertion of the early transposable element ETn in the Fas gene, which causes a striking

reduction in Fas mRNA expression and is associated clinically with marked acceleration of the lupus-like disease [39]. Levels of circulating immune complexes rise enormously from about three months of age in MRL-lpr/lpr but not in MRL mice. In this study, we used MRL/lpr mice as a SLE mouse model to indicate that SHED are an appropriate population of postnatal stem cells for SLE treatment as seen in BMMSC-mediated therapy.

SHED are derived from a very accessible tissue resource and capable of providing enough cells for potential clinical application via high proliferation rate and expression of telomerase [21]. The reason that SHED transplantation showed optimal therapeutic effect may be associated with the fact that SHED showed superior immunomodulatory effects compared to BMMSCs in terms of recovering Tregs/Th17 ratio and reducing Th17





cell levels in peripheral blood. In addition, SHED transplantation, as seen in BMMSC transplantation, is capable of recovering trabecular bone and inhibiting osteoclast activity, suggesting that SHED transplantation, as seen in BMMSC transplantation, could lead the reconstruction of osteoblastic niche to improve SLE disorders in SLE patients and a SLE-like murine model [17]. Therefore, SHED may be an appropriate stem cell resource for treating immune disorders via improved immunomodulatory properties. Systemic infusion of SHED fails to show a significant promoting Treg level in SLE-like mice as seen in an *in vitro* co-culture system, which may be associated with a complex *in vivo* condition that hardly compares to a simple co-culture system. However, SHED infusion resulted in a significantly up-regulated level of the ratio between Tregs and Th17 cells. This is an important index indicating immunomodulatory function of SHED due to the fact that Tregs prevent autoimmunity and Th17 cells promote autoimmunity and inflammation [40].

The transition from deciduous teeth to adult permanent teeth is a unique and dynamic process in which the development and eruption of permanent teeth is coordinated with the resorption of deciduous teeth. We found that exfoliated deciduous tooth crowns contain a remnant of living pulp comprised of a normal dental pulp structure, including connective tissue, blood vessels, and odontoblasts [21]. We demonstrated that these remnants of pulp tissues in exfoliated deciduous teeth contain SHED [21]. These studies provide the first evidence that a naturally occurring exfoliated organ contains stem cells with the ability to form multiple phenotypes, and that these stem cells may offer a unique stem cell resource for potential clinical applications. SHED are very easily acquired from exfoliated teeth and can be expanded *ex vivo* to achieve sufficient numbers of cells for tissue regeneration such as repairing parietal defects [24].

## Conclusions

SHED possess similar stem cell properties as those seen in BMMSCs, including osteo/odontogenic and adipogenic differentiation *in vitro*, forming mineralized tissue *in vivo*, and expression of extensive mesenchymal stem cell markers. Moreover, systemic SHED transplantation is capable of offering similar, if not better, therapeutic effect on SLE murine model, suggesting that easily accessed SHED may be a feasible stem cell source for stem cell therapies.

**Additional file 1. Supplementary Materials and methods and 2 supplementary tables.** A PDF file containing supplementary Materials and methods and 2 supplementary tables: Table S1 displays information on antibodies; and Table S2, lists PCR primers.

## Abbreviations

ALP = alkaline phosphatase; BMMSC = bone marrow mesenchymal stem cells; BrdU = bromodeoxyuridine; C3 = complement 3; CFU = colony forming units-fibroblastic; CTX = C-terminal telopeptides of type I collagen; DSP = dentin sialoprotein; FCM = flow cytometry; HA/TCP = hydroxyapatite tricalcium phosphate; IL = interleukin; LPL = lipoprotein lipase; OCN = osteocalcin; PBMCs = peripheral blood mononuclear cells; PCR = polymerase chain reaction; PPAR $\gamma$ 2 = peroxisome proliferator-activated receptor  $\gamma$ 2; Runx2 = Runt related transcription factor 2; Th17 = T helper 17; TRAP = telomeric repeat amplification protocol; Tregs = regulatory T cells; TUNEL = Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling; SHED = Stem cells from human exfoliated deciduous teeth; SLE = systemic lupus erythematosus; sRANKL = soluble receptor activator for nuclear factor  $\kappa$ B ligand.

## Competing Interests

The authors declare that they have no competing interests.

## Authors' contributions

TY and KA collected and assembled data, and worked on data analysis and interpretation. CC collected and assembled data. YL worked on data analysis and interpretation. YS, SG and SW worked on conception and design, and SS worked on conception and design, data analysis and interpretation and wrote the manuscript.

## Acknowledgements

This work was supported by grants from the National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services (R01DE017449 to S.S. and ARRA R01DE019413 to S.S. and Y.S.).

## Author details

<sup>1</sup>Center for Craniofacial Molecular Biology, University of Southern California School of Dentistry, 2250 Alcazar Street, CSA 103, Los Angeles, CA 90033, USA. <sup>2</sup>Department of Oral Anatomy and Cell Biology, Kyushu University Graduate School of Dental Science, Fukuoka 812-8582, Japan. <sup>3</sup>Department of Molecular Genetics, Microbiology and Immunology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 661 Hoes Lane, Piscataway, NJ 08854, USA. <sup>4</sup>Mesenchymal Stem Cell Group, Division of Haematology, Institute of Medical and Veterinary Science/Hanson Institute/CSCR, University of Adelaide, Frome Rd, Adelaide, SA 5000, Australia. <sup>5</sup>Salivary Gland Disease Center and the Molecular Laboratory for Gene Therapy & Tooth Regeneration, Capital Medical University School of Stomatology, Tian Tan Xi Li No.4, Beijing 100050, China.

Received: 18 Jul 2009 Accepted: 15 Mar 2010 Published: 15 Mar 2010

## References

1. Prockop DJ: **Marrow stromal cells as stem cells for nonhematopoietic tissues.** *Science* 1997, **276**:71-74.
2. Bianco P, Riminucci M, Gronthos S, Robey PG: **Bone marrow stromal stem cells: nature, biology, and potential applications.** *Stem Cells* 2001, **19**:180-192.
3. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV: **Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo.** *Transplantation* 1974, **17**:331-340.
4. Owen M, Friedenstein AJ: **Stromal stem cells: marrow-derived osteogenic precursors.** *Ciba Found Symp* 1988, **136**:42-60.
5. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: **Multilineage potential of adult human mesenchymal stem cells.** *Science* 1999, **284**:143-147.
6. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R: **Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.** *Exp Hematol* 2002, **30**:42-48.
7. Uccelli A, Pistoia V, Moretta L: **Mesenchymal stem cells: A new strategy for immunosuppression?** *Trends Immunol* 2007, **28**:219-226.
8. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Riso M, Gualandi F, Mancardi GL, Pistoia V, Uccelli A: **Human mesenchymal stem cells modulate B-cell functions.** *Blood* 2006, **107**:367-372.
9. Rasmuson I, Le Blanc K, Sundberg B, Ringden O: **Mesenchymal stem cells**

- stimulate antibody secretion in human B cells. *Scand. J Immunol* 2007, **65**:336–343.
10. Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F: **Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle.** *Transplantation* 2007, **83**:71–76.
  11. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L: **Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation.** *Blood* 2006, **107**:1484–1490.
  12. Aggarwal S, Pittenger MF: **Human mesenchymal stem cells modulate allogeneic immune cell responses.** *Blood* 2005, **105**:1815–1822.
  13. Le Blanc K, Frassonni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O; **Developmental Committee of the European Group for Blood and Marrow Transplantation: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.** *Lancet* 2004, **363**:1439–1441.
  14. Chen X, Armstrong MA, Li G: **Mesenchymal stem cells in immunoregulation.** *Immunol Cell Biol* 2006, **84**:413–421.
  15. Koç ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L, Fox RM, Szekely EM, Tainer N, Lazarus HM: **Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy.** *J Clin Oncol* 2000, **18**:307–316.
  16. Noort WA, Kruijselbrink AB, in't Anker PS, Kruger M, van Bezooijen RL, de Paus RA, Heemskerk MH, Löwik CW, Falkenburg JH, Willemze R, Fibbe WE: **Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34 cells in NOD/SCID mice.** *Exp Hematol* 2002, **30**:870–878.
  17. Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S: **Mesenchymal stem cell transplantation reverses multi-organ dysfunction in systemic lupus erythematosus mice and humans.** *Stem Cells* 2009, **27**:1421–1432.
  18. Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, Osaki M, Kawamata M, Kato T, Okochi H, Ochiya T: **IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury.** *Stem Cells* 2008, **26**:2705–2712.
  19. Cho KS, Park HK, Park HY, Jung JS, Jeon SG, Kim YK, Roh HJ: **IFATS collection: Immunomodulatory effects of adipose tissue-derived stem cells in an allergic rhinitis mouse model.** *Stem Cells* 2009, **27**:259–265.
  20. Wada N, Menicanin D, Shi S, Bartold PM, Gronthos S: **Immunomodulatory properties of human periodontal ligament stem cells.** *J Cell Physiol*. 2009, **219**:667–676.
  21. Miura M, Gronthos S, Zhao M, Lu B, Fisher LW, Robey PG, Shi S: **SHED: Stem cells from human exfoliated deciduous teeth.** *Proc Natl Acad Sci U S A* 2003, **100**:5807–5812.
  22. Laino G, Graziano A, d'Aquino R, Pirozzi G, Lanza V, Valiante S, De Rosa A, Naro F, Vivarelli E, Papaccio G: **An approachable human adult stem cell source for hard-tissue engineering.** *J Cell Physiol*. 2006, **206**:693–701.
  23. Zheng Y, Liu Y, Zhang CM, Zhang HY, Li WH, Shi S, Le AD, Wang SL: **Stem cells from deciduous tooth repair mandibular defect in swine.** *J Dent Res* 2009, **88**:249–254.
  24. Seo BM, Sonoyama W, Coppe C, Kikui T, Akiyama K, Lee JS, Shi S: **SHED repair critical-size calvarial defects in immunocompromised mice.** *Oral Diseases* 2008, **14**:428–434.
  25. Yamaza T, Miura Y, Akiyama K, Bi Y, Sonoyama W, Gronthos S, Chen W, Le A, Shi S: **Mesenchymal Stem Cell-Mediated Ectopic Hematopoiesis Alleviates Aging-Related Phenotype in Immunocompromised Mice.** *Blood* 2009, **113**:2595–2604.
  26. Shi S, Gronthos S, Chen S, Reddi A, Counter CM, Robey PG, Wang CY: **Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression.** *Nat Biotechnol* 2002, **20**:587–591.
  27. Gronthos S, Mankani M, Brahimi J, Robey PG, Shi S: **Post-natal dental pulp stem cells in vivo and in vitro.** *Proc Natl Acad Sci U S A* 2000, **97**:13625–13630.
  28. Yamaza T, Miura Y, Bi Y, Liu Y, Akiyama K, Sonoyama W, Patel V, Gutkind S, Young M, Gronthos S, Le A, Wang CY, Chen W, Shi S: **Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents.** *PLoS ONE* 2008, **3**:e2615.
  29. Liu Y, Zheng Y, Ding G, Fang D, Zhang C, Bartold PM, Gronthos S, Shi S, Wang S: **Periodontal ligament stem cell-mediated treatment for periodontitis in miniature swine.** *Stem Cells* 2008, **26**:1065–1073.
  30. La Cava A: **T-regulatory cells in systemic lupus erythematosus.** *Lupus* 2008, **17**:421–425.
  31. Garrett-Sinha LA, John S, Gaffen SL: **IL-17 and the Th17 lineage in systemic lupus erythematosus.** *Curr Opin Rheumatol* 2008, **20**:519–525.
  32. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H: **Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction.** *J Exp Med* 2006, **203**:2673–2682.
  33. El-Badri NS, Hakkı A, Ferrari A, Shamekh R, Good RA: **Autoimmune disease: is it a disorder of the microenvironment?** *Immunol Res* 2008, **41**:79–86.
  34. Cordeiro AC, Isenberg DA: **Novel therapies in lupus - focus on nephritis.** *Acta Reumatol Port* 2008, **33**:157–169.
  35. Rahman A, Isenberg DA: **Systemic lupus erythematosus.** *N Engl J Med* 2008, **358**:929–939.
  36. Kyttaris VC, Juang YT, Tsokos GC: **Immune cells and cytokines in systemic lupus erythematosus: an update.** *Curr Opin Rheumatol* 2005, **17**:518–522.
  37. Crispin JC, Tsokos GC: **Novel molecular targets in the treatment of systemic lupus erythematosus.** *Autoimmun Rev* 2008, **7**:256–261.
  38. Ramanujam M, Davidson A: **Targeting of the immune system in systemic lupus erythematosus.** *Expert Rev Mol Med* 2008, **10**:e2.
  39. Neubert K, Meister S, Moser K, Weisel F, Masada D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE: **The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.** *Nat Med* 2008, **14**:748–755.
  40. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H: **Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid.** *Science* 2007, **317**:256–260.

doi:10.1186/scrt5

Cite this article as: Yamaza T, et al.: Immunomodulatory properties of stem cells from human exfoliated deciduous teeth. *Stem Cell Research & Therapy* 2010, 1:5.